Position in NUVB
as of Jun 30, 2026
· filed Jul 10, 2026
Position Value
$732,152
+$639,416 QoQ
Shares Held
128,900
+211.4% QoQ
Ownership
0.037%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#3
of 31 holders
Holding Since
Dec 2021
5 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in NUVB Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Handelsbanken Fonder AB holds $686,434,691 across 88 Biotechnology names. NUVB ranks #84 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
218,292 | $108,432,185 | |
| 2 | HALO |
Halozyme Therapeutics, Inc.
|
631,899 | $49,458,734 | |
| 3 | ARGX |
Argenx SE
|
52,653 | $48,849,873 | |
| 4 | RVMD |
Revolution Medicines, Inc.
|
212,275 | $39,754,862 | |
| 5 | CYTK |
Cytokinetics Inc
|
405,000 | $34,501,950 | |
| 6 | KRYS |
Krystal Biotech, Inc.
|
90,407 | $33,601,569 | |
| 7 | REGN |
Regeneron Pharmaceuticals, Inc.
|
52,328 | $32,628,601 | |
| 8 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
107,255 | $32,286,972 |
All Filings in NUVB
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $732,152 | 128,900 | Shares | Sole | 2026-07-10 | |
| 2022-09-30 | $92,736 | 41,400 | Shares | Sole | 2022-10-27 | |
| 2022-06-30 | $134,136 | 41,400 | Shares | Sole | 2022-08-03 | |
| 2022-03-31 | $230,388 | 43,800 | Shares | Sole | 2022-05-11 | |
| 2021-12-31 | $372,300 | 43,800 | Shares | Sole | 2022-02-08 | |
| No filing history on record for this holder in this stock. | ||||||